Form 4: Neurocrine Biosciences Officer Reports Stock Transactions

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Summary

• On January 31, 2025, David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, exercised restricted stock units (RSUs) converting into 2,096 shares of common stock.
• Simultaneously, Mr. Boyer sold 1,104 shares of Neurocrine Biosciences common stock at a weighted average price of $152.9433 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 1, 2022.
• Following these transactions, Mr. Boyer directly owns 1,369 shares of common stock and 2,096 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company.

Future Outlook

The RSU award will vest as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates